At physiological concentrations (e.g., approximately 5 μM in tumor tissues), ICA acts as a competitive partial AhR agonist, binding to AhR with higher affinity than the immunosuppressive ligand Kyn (112). The gene discussed is AHR; the disease is neoplasm.